IBB mid-caps

The mid-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) fell 2.1% and underperformed the SPDR S&P 500 ETF (SPY), which fell 0.2%. As of April 11, 2016, IBB holds 28 mid-cap stocks in its portfolio. Among them, 23 stocks fell, and only five stocks rose. IBB’s mid-cap stocks account for 20.8% of its portfolio.

IBB Mid-Caps: Medicines Company’s Carbavance, Fast-Track Status

The above graph reflects the daily changes of IBB mid-cap stocks compared to the SPDR S&P 500 ETF (SPY) in April to date. IBB mid-caps have outperformed SPY with a return of 6.5%.

Carbavance received fast-track status from the FDA

In a press release, the Medicines Company (MDCO) announced that “the U.S. Food and Drug Administration ([or] FDA) has granted Fast Track Designation to the investigational agent CARBAVANCE (meropenem-vaborbactam) for the treatment of complicated urinary tract infections ([or] cUTI). CARBAVANCE is the combination of the carbapenem antibiotic, meropenem, with the novel beta-lactamase inhibitor, vaborbactam (formerly known as RPX7009), that is being developed for the treatment of gram-negative infections, including those due to carbapenem-resistant Enterobacteriaceae (CRE).”

The Medicines Company closed at $32.30, a fall of 3.5% from its previous day’s close. Year-to-date, the stock has fallen 13.5%. Year-to-date returns for peers Ligand Pharmaceuticals (LGND), Kite Pharma (KITE), and Myriad Genetics (MYGN) were 6.3%, -19.4%, and -10.5%, respectively. MDCO stock has a book value of $10.52 per share. With its current price, the stock is trading at a price-to-book value of ~3.1x. The Medicines Company has a weight of 0.4% in IBB’s portfolio.

Latest articles

Apple (AAPL) investors have had a roller coaster week. Apple stock has lost just under 2% in a week, ending on August 23, 2019.

Competition taking a toll on Netflix as its share of US subscription video streaming market keep falling as rivals gain ground.

Crude oil production continues to rise, and oil prices remain at $50. Despite that, US energy stocks aren’t getting investors’ interest.

Apple stock fell 4.6% as the US-China trade war intensified today. China warned of tariffs on more US goods, followed by Trump's tweeted response.

In response to new tariffs from China and President Trump's tweets, the market tanked to session lows on Friday. The DJIA nosedived more than 600 points.

Coverage on Cresco Labs has increased from seven analysts in July to nine in August. Six analysts favor a “strong buy,” and three recommend a “buy.”